Business Wire

CoinDeal Celebrates Wolverhampton Wanderers Sponsorship Renewal with the Launch of an Innovative Free Token

Share

Global cryptocurrency exchange platform, CoinDeal, has confirmed the extension of its sponsorship of Wolverhampton Wanderers for a further year and, to celebrate, has launched an innovative new token, CDL, as the company expands into the USA.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190701005325/en/

Jeff Shi (Executive Chairman Wolverhampton Wanderers) and Kajetan Máckowiak (Co-founder CoinDeal) (Photo: Business Wire)

Jeff Shi (Executive Chairman Wolverhampton Wanderers) and Kajetan Máckowiak (Co-founder CoinDeal) (Photo: Business Wire)

CoinDeal’s sleeve sponsorship of the English Premier League club will mean its logo continues to appear on the first team playing kit.

The original deal, the world’s first cryptocurrency exchange football sponsorship, coincided with Wolves’ remarkable seventh-place finish in the English Premier League that secured European football for the club for the first time in nearly 40 years.

CoinDeal’s new token, CDL, is available now from www.coindeal.com completely free of charge to 320,000 existing users and to 130,000 new CoinDeal users. The CDL token provides higher liquidity within the CoinDeal exchange and additional pairings with cryptocurrencies and fiats.

The variety of benefits continue, with lower trading fees, advanced trading features, Fast Pass priority user support and a multi-tier staking system that can remove fees altogether.

The extension of the Wolves sponsorship and the launch of the CDL token follows a rapid rise for CoinDeal over the last 12 months. CoinDeal has secured over 320,000 users, achieved a record 24 hour trade volume of over US$32million earlier this year* and was listed by The Tie (www.thetie.io) as the cryptocurrency exchange with the fourth highest expected volume in 2019**.

CoinDeal’s move into the US marketplace is designed to build on this momentum, continue the levels of growth and cement CoinDeal’s position as a premier global cryptocurrency exchange. CoinDeal will initially be available in 14 states*** and will expand to over 40 with a USD pairing by 2020. The CoinDeal platform currently allows users from the selected states to register and receive free CDL tokens.

Kajetan Maćkowiak, CoinDeal co-founder commented, “We are delighted to renew the contract with Wolverhampton Wanderers following the success of our first year as official sponsor and will continue to work closely with the club to communicate the CoinDeal message to a global audience. We wish them good luck for another successful season in the Premier League and throughout their Europa League campaign.

“In the last 12 months we have seen CoinDeal grow rapidly and we are delighted to announce that we now have over 320,000 users globally. As the CoinDeal brand goes from strength to strength, we are excited about the growth opportunity that the move into the US market offers.

“The launch of the CDL token is designed to help accelerate this growth, it is a fantastic opportunity for new users to start trading for free and for all CoinDeal users to take advantage of a variety of other benefits on a premier global Cryptocurrency exchange.”

In addition to the expansion into the US marketplace, CoinDeal has received membership into the VQF (Financial Services Standards Association). The VQF licence not only confirms CoinDeal’s financial credibility but also allows it to start operations in Switzerland as CoinDeal Swiss.

For more information please visit www.coindeal.com

Video: CoinDeal and Wolverhampton Wanderers sponsorship renewal - view here

Notes to editors:

*CoinDeal record daily trade volume on 15/05/19: US$32,675,859
**The Tie – Top 100 CryptoCurrency Exchanges by expected volume
***Initial US states include Indiana, Idaho, Kansas, Montana, New Hampshire, New Jersey, Pennsylvania, Tennessee, Texas, Virginia and Wisconsin.

CDL Tokens

The CDL token was created using EOS blockchain and will offer fast transaction times and significantly reduced network fees in comparison to most ERC20 tokens.

The total supply of CDL tokens is 50,000,000 and following the completion of the giveaway CoinDeal will launch a variety of pairings with crypto and fiats.

CoinDeal

CoinDeal offers access to over 55 crypto markets including the most popular cryptocurrencies such as Ethereum, Bitcoin or Litecoin. CoinDeal also offers access to many FIAT currencies including the Euro (EUR), Dollar (USD), British Pound (GBP), Polish Zloty (PLN), Rouble (RUB) and Korean Won (KRW).

CoinDeal stands apart from other companies as they allow their users to choose new cryptocurrency by voting so that everyone can take part in growth of the trading platform.

Contact information

Katarzyna Pergoł
media@coindeal.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease19.7.2019 17:59:00 CESTPress release

Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA® (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behçet’s Disease. OTEZLA, an oral, selective inhibitor of phosphodiesterase 4 (PDE4), is the first and only approved treatment option for oral ulcers associated with Behçet’s Disease, a rare, chronic, multisystem inflammatory disease that is difficult to treat. “Oral ulcers are a recurring and debilitating manifestation that affects nearly everyone living with Behçet’s Disease, and have an important negative impact on the quality of life for these patients,” said Yusuf Yazici, M.D., Clinical Associate Professor, Department of Medicine, New York University Langone Health. “In the clinical trial, OTEZLA demonstrated improvements in measures of oral ulcers at week 12. OTEZLA has the potential to be a needed treatment option for U.S. patients and their physicians, who

Abiraterone Acetate Included in World Health Organisation’s Essential Medicines List for the Treatment of Metastatic Castration-Resistant Prostate Cancer19.7.2019 13:05:00 CESTPress release

The Janssen Pharmaceutical Companies of Johnson & Johnson is delighted with the recent announcement from the World Health Organisation (WHO) to include abiraterone acetate (ZYTIGA ® ) for the treatment of metastatic castration-resistant prostate cancer (mCRPC), in the updated Essential Medicines List, published on 9th July 2019.1,2 The WHO’s Essential Medicines List is a core guidance document that helps countries prioritise critical health products that are recommended to be widely available and affordable throughout health systems.1 “The inclusion of abiraterone acetate in the WHO Essential Medicines List highlights the critical role that this treatment can play in improving the lives of patients living with mCRPC and their families,” said Dr. Joaquín Casariego, Janssen Therapeutic Area Lead Oncology for Europe, Middle East & Africa, Janssen-Cilag S.A. “I am proud that we are working hard to impact survival and quality of life by developing and providing innovative medicines which ar

Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis19.7.2019 12:30:00 CESTPress release

Gilead Sciences, Inc. (NASDAQ: GILD) announced today that it has licensed three preclinical antiviral programs from Novartis, including investigational agents with the potential to treat human rhinovirus, influenza and herpes viruses. Under the agreement, Gilead will acquire exclusive global rights to develop and commercialize novel small molecules against three undisclosed targets. Novartis will receive an upfront payment and is eligible to receive up to an additional $291 million in potential milestone payments upon achievement of certain development and commercial milestones, as well as royalties on annual net sales. “Today’s announcement builds on Gilead’s heritage in antiviral research and development. We look forward to applying this expertise to advance the development of potential new treatments for viruses with limited therapeutic options,” said John McHutchison AO, MD, Gilead’s Chief Scientific Officer and Head of Research and Development. Gilead’s antiviral portfolio include

Schlumberger Announces Second-Quarter 2019 Results19.7.2019 11:00:00 CESTPress release

Schlumberger Limited (NYSE: SLB) today reported results for the second quarter of 2019. (Stated in millions, except per share amounts) Three Months Ended Change Jun. 30, 2019 Mar. 31, 2019 Jun. 30, 2018 Sequential Year-on-year Revenue $8,269 $7,879 $8,303 5% 0% Pretax segment operating income $968 $908 $1,094 7% -12% Pretax segment operating margin 11.7% 11.5% 13.2% 17 bps -148 bps Net income - GAAP basis $492 $421 $430 17% 14% Net income, excluding charges & credits* $492 $421 $594 17% -17% Diluted EPS - GAAP basis $0.35 $0.30 $0.31 17% 13% Diluted EPS, excluding charges & credits* $0.35 $0.30 $0.43 17% -19% North America revenue $2,801 $2,738 $3,139 2% -11% International revenue $5,463 $5,037 $5,065 8% 8% North America revenue, excluding Cameron $2,243 $2,178 $2,546 3% -12% International revenue, excluding Cameron $4,761 $4,469 $4,387 7% 9% *These are non-GAAP financial measures. See section titled "Charges & Credits" for details. Schlumberger Chairman and CEO Paal Kibsgaard commente

Schlumberger Appoints Olivier Le Peuch as CEO19.7.2019 10:46:00 CESTPress release

Schlumberger Limited (NYSE: SLB) announced today that its Board of Directors has appointed Olivier Le Peuch as its Chief Executive Officer and member of the Schlumberger Board, effective August 1, 2019. Mr. Le Peuch succeeds Paal Kibsgaard, who will retire as Chief Executive Officer effective that same date. Also effective August 1, Mr. Kibsgaard will step down as Chairman of the Board and retire as a member of the Board of Directors. Mr. Kibsgaard will retire after more than 22 years of service to the Company, including eight years as CEO and four years as Chairman. Effective the same date, Mark G. Papa, a current non-independent director, will become non-executive Chairman of the Board. Peter Currie will continue to serve as the Board’s Lead Independent Director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190719005161/en/ Olivier Le Peuch is appointed Chief Executive Officer and a member of the Schlumberger Board, effe

Fluke Corporation Acquires Industrial Reliability Leader PRÜFTECHNIK19.7.2019 10:00:00 CESTPress release

Fluke Corp., the global leader in test and measurement instruments, has acquired Ismaning, Germany-based PRÜFTECHNIK, a market leader in precision laser shaft alignment, condition monitoring, and non-destructive testing. “Fluke’s acquisition of PRÜFTECHNIK reflects the growing importance our customers place on reliability systems to keep their equipment in optimum operating condition,” said Marc Tremblay, president of Fluke Corporation. “This business will help us usher in the next generation of solutions for our industrial customers.” Fluke Corporation For information on Fluke tools and applications, or to find the location of your nearest distributor, contact Fluke Corporation, P.O. Box 9090, Everett, WA USA 98206, call (800) 44-FLUKE (800-443-5853), fax (425) 446-5116, e-mail fluke-info@fluke.com or visit the Fluke Web site at http://www.fluke.com. About Fluke Founded in 1948, Fluke Corporation is the world leader in compact, professional electronic test tools and software for measu